Xcell Therapeutics
Financials
Valuation Metrics
Xcell Therapeutics's Market Cap is ₩176B. At end of 2025 it was ₩287B. Ranked #2368 of 2,421 in KR market (top 98%), #1594 of 1,640 on KOSDAQ (top 97%), #227 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 98%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 17.59B KRW | KR#2,368/2,421 Sec#227/231 |
| Revenue | 4.36B KRW | KR#2,349/2,421 Sec#200/231 |
| Net Income | -11.37B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 12.63B KRW | KR#2,396/2,421 Sec#228/231 |
| Net Assets | 4.33B KRW | KR#2,394/2,421 Sec#228/231 |
| Employees | 68 | KR#1,905/2,421 Sec#166/231 |
| Value | ||
| P/B | 4.07x | KR#2,196/2,421 Sec#181/231 |
| P/S | 4.04x | KR#2,084/2,421 Sec#136/231 |
| FCF Yield | -58.95% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROA | -90.00% | KR#2,394/2,421 Sec#226/231 |
| Op. Margin | -259.36% | KR#2,344/2,421 Sec#190/231 |
| Revenue Growth | 193.30% | KR#42/2,421 Sec#11/231 |
| Financial Health | ||
| Debt Ratio | 191.88% | KR#2,078/2,421 Sec#216/231 |
| Total Debt | 4.57B KRW | KR#1,807/2,421 Sec#174/231 |
| FCF | -10.37B KRW | KR#1,720/2,421 Sec#150/231 |
| Cash | 3.93B KRW | KR#2,092/2,421 Sec#195/231 |
| Current Ratio | 1.28x | KR#1,421/2,421 Sec#149/231 |
| Performance | ||
| 1Y Return | -64.33% | KR#2,255/2,421 Sec#212/231 |
| 1M Return | -20.30% | KR#2,303/2,421 Sec#210/231 |
| From 52W High | -71.40% | KR#2,221/2,421 Sec#193/231 |
| 1Y MDD | -65.53% | KR#1,777/2,421 Sec#147/231 |
| Trading | ||
| Volume | 54,840 shares | KR#1,087/2,421 Sec#107/231 |
| Trading Value | 55.6M KRW | KR#1,797/2,421 Sec#184/231 |
| Foreign Own. | 1.58% | KR#1,802/2,421 Sec#176/231 |
| Per Share | ||
| EPS | -657 KRW | KR—/2,421 Sec—/231 |
| BPS | 250 KRW | KR#2,412/2,421 Sec#231/231 |
Company Info
Excell Therapeutics, established in 2015 and listed on KOSDAQ in 2024 as a technology growth company, specializes in cell culture media. The company primarily manufactures and supplies chemically defined media, 'CellCor', which excludes animal and human-derived substances crucial for the cell and gene therapy industry, from its GMP production facilities. It has developed the cell-customized medium development platform technology XPorT and is expanding its business into advanced biopharmaceuticals. Excell Therapeutics is headquartered in Gangnam-gu, Seoul.